The analgesic potential of clostridial neurotoxin derivatives

Expert Opinion on Investigational Drugs

Volumn 13, Issue 11, 2004, Pages 1437-1443

  Foster, Keith A ^a  

^a HPA   (United Kingdom)

Author keywords

Analgesic; Botulinum neurotoxin; Clostridial neurotoxin; Endopeptidase; Erythrina cristagalli; Migraine; Neurogenic; Neuropeptide; SNARE complex; SNARE protein; Substance P

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; HYBRID PROTEIN; LECTIN; MORPHINE; NEUROTRANSMITTER; TETANUS TOXIN;

ACETYLCHOLINE RELEASE; ANALGESIA; ANALGESIC ACTIVITY; AUTONOMIC NEUROPATHY; CHOLINERGIC NERVE; CHRONIC PAIN; CLOSTRIDIUM; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; IN VIVO STUDY; LETHALITY; NEUROMUSCULAR DISEASE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NOCICEPTIVE RECEPTOR; NONHUMAN; PERIPHERAL NERVE; PROTEIN TERTIARY STRUCTURE; REVIEW; SENSORY NERVE; SEROTYPE; STRUCTURE ACTIVITY RELATION; SYNDROME;

ANALGESICS; ANIMALS; CLOSTRIDIUM; HUMANS; NEUROTOXINS; PAIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 8844265257     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.11.1437     Document Type: Review

References (46)

1. BLASI J, CHAPMAN ER, LINK E et al.: Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature (1993) 365:160-163.
2. MONTECUCCO C, SCHIAVO G: Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. (1994) 13(1):1-8.
3. SCHIAVO G, MATTEOLI M, MONTECUCCO C: Neurotoxins affecting neurocytosis. Physiol. Rev. (2000) 80:717-766.
4. SCOTT AB: Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology (1980) 87 1044-1049.
5. CARRUTHERS J, CARRUTHERS A: Botox: beyond wrinkles. Clin. Dermatol. (2004) 22:89-93.
6. CORDIVARI C, MISRA VP, CATANIA S, LEES AJ: New therapeutic indications for botulinum toxins. Mov. Disord. (2004) 19 8):S157-S161.
7. PANICKER JN, MUTHANE UB: Botulinum toxins: Pharmacology and its current therapeutic evidence for use. Neurology India (2003) 51(4):455-460.
8. THANT Z-S, TAN E-K: Emerging therapeutic applications of botulinum toxin. Med. Sci. Monit. (2003) 9(2):RA40-RA48.
9. RAJ PP: Botulinum toxin therapy in pain management. Anesthesiology Clin. N. Am. (2003) 21:715-731.
10. ROYAL M: Botulinum toxins in pain management. Phys. Med. Rehabil. Clin. N. Am. (2003) 14:805-820.
11. ARGOFF CE: The use of botulinum toxins for chronic pain and headaches. Curr. Treat. Options Neurol. (2003) 5:483-492.
12. ARGOFF CE: A focused review on the use of botulinum toxins for neuropathic pain. Clin. J. Pain (2002) 18:S177-S181.
13. AREZZO JC: Possible mechanisms for the effects of botulinum toxin on pain. Clin. J. Pain (2002) 18:S125-S132.
14. MENSE S: Neurobiological basis for the use of botulinum toxin in pain therapy. J. Neurol. (2004) 251(Suppl. 1)I1-I7.
15. PURKISS JR, WELCH MJ, DOWARD S, FOSTER KA: Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem. Pharmacol. (2000) 59:1403-1406.
16. WELCH MJ, PURKISS JR, FOSTER KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicology (2000) 38:245-258.
17. ISHIKAWA H, MITSUI Y, YOSHITOMI T et al.: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J. Ophthalmol. (2000) 44:106-109.
18. AOKI KR: Pharmacology and immunology of botulinum toxin serotypes. J. Neurol. (2001) 248(Suppl. 1):3-10.
19. BORODIC GE, ACQUADRO M, JOHNSON EA: Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin. Investig. Drugs (2001) 10:1531-1544.
20. AOKI KR: Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache (2003) 43(Suppl. 1):S9-S15.
21. CUI M, KHANIJOU S, RUBINO, AOKI KR: Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain (2004) 107(1-2):125-133.
22. MORENILLA-PALAO C, PLANELLS-CASES R, GARCIA-SANZ N, FERRER MONTIEL A: Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J. Biol. Chem. (2004) 279:25665-25672.
23. SIMPSON LL: Molecular pharmacology of botulinum toxin and tetanus toxin. Ann. Rev Pharmacol Toxicol (1986) 26:427-453.
24. HALPERN JL, LOFTUS A: Characterisation of the receptor binding domain of tetanus toxin. J. Biol. Chem. (1993) 268 11188-11192.
25. SHONE CC, HAMBLETON P, MELLING J: Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity. Eur. J. Biochem. (1985) 151:75-82.
26. 2-terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesicles. Eur. J. Biochem. (1987) 167:175-180.
27. LACY B, TEPP W, COHEN AC et al.: Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. (1998) 5:898-902.
28. SWAMINATHAN S, ESWARAMOORTHYS: Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. (2000) 7:693-699.
29. UMLAN TC, WINGERT LM, SWAMINATHAN S et al.: Structure of the receptor binding fragment HC of tetanus neurotoxin. Nat. Struct. Biol. (1997) 4:788-792.
30. HANSON MA, STEVENS RC: Structural view of botulinum neurotoxin in numerous functional states. In: Scientific and Therapeutic Aspects of Botulinum Toxin. MF Brin, J Jankovic, M Hallett (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2002):11-27.
31. SWAMINATHAN S, ESWARAMOORTHY S: Crystal structure of Clostridium botulinum neurotoxin serotype B. In: Scientific and Therapeutic Aspects of Botulinum Toxin. MF Brin, J Jankovic, M Hallett (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2002):29-39.
32. SUTTON JM, SPAVEN L, SILMAN N et al.: The receptor binding domains of clostridial neurotoxins. In: Scientific and Therapeutic Aspects of Botulinum Toxin. MF Brin, J Jankovic, M Hallett (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2002):41-48.
33. CHADDOCK JA, HERBERT MH, LING RJ et al.: Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. Protein Expr. Purif. (2002) 25:219-228.
34. CHADDOCK JA, PURKISS JR, FRIIS LM et al.: Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A. Infect. Immun. (2000) 68:2587-2593.
35. CHADDOCK JA, PURKISS JR, DUGGAN MJ et al.: A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors (2000) 18:147-155.
36. SOLLNER TSW, WHITEHEART M, BRUNNER H et al.: SNAP receptors implicated in vesicle targeting and fusion. Nature (1993) 362:318-324.
37. STREIT WJ, SCHULTE BA, BALENTINE DJ, SPICER SS: Histochemical localization of galactose-cotaining glycoconjugates in sensory neurons and their processes in the central and peripheral nervous system of the rat. J. Histochem. Cytochem. (1985) 33:1042-1052.
38. STREIT WJ, SCHULTE BA, BALENTINE DJ, SPICER SS: Evidence for glyco conjugate in nociceptive primary sensory neurons and its origin from the Golgi complex. Brain Res (1986) 377:1-17.
39. DUGGAN MJ, QUINN CP, CHADDOCK JA, PURKISS JR et al.: Inhibition of release of neurotransmitters from dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J. Biol. Chem. (2002) 277(38):34846-34852.
40. CHADDOCK JA, PURKISS JR, ALEXANDER FCG et al.: Retargeted clostridial endopeptidases: inhibiiton of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain. Mov. Disord. (2004) 19(Suppl. 8):S42-S47.
41. KELLER JE, NEALE EA, OYLER G, ADLER M: Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. (1999) 456(1):137-142.
42. KELLER JE, NEALE EA: The role of the synaptic protein SNAP-25 in the potency of botulinum neurotoxin type A. J. Biol. Chem. (2001) 276(16):13476-13482.
43. FERNANDEZ-SALAS E, STEWARD LE, HO H et al.: Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc. Nat. Acad. Sci. USA (2004) 101(9):3208-3213.
44. DOLLY O: Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache (2004) 43 Suppl. 1):S16-S24.
45. AOKI KR, RUBINO J, KHANIJOU S et al.: Retargeted clostridial endopeptidase: antinociceptive activity in in vivo models of pain. International Association for the Study of Pain, 10th World Congress on Pain, San Diego, CA, USA (2002) (Abstract 831).
46. LACY DB, TEPP W, COHEN AC et al.: Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. (1998) 5:898-902.